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2.1      Introduction
With analysis of the human genome complete 
(actually, 98.8%), the Human Genome Project was 
declared complete on April 14, 2003, heralding 
the arrival of a genuine post-genome era.
In fact for about five years now, research 
strateg ies have been targeted to su it th is 
post - genome era. In Japan, genome - based 
research has also been promoted such as that on 
protein structure/function analysis, sugar-chain 
structure/function analysis and disease-related 
SNP analysis as part of post genome research.
In this context, research focusing on the causal 
relationship between diseases and the human 
genome has become internationally widespread. 
In recent years, it has been reported that histone 
protein (which binds to genome DNA) or genome 
DNA in the cells from patients with various types 
of cancers and with common diseases might 
be modified by enzymes such as methylase 
(methylation) or acetylase (acetylation). This 
type of modification is considered to affect gene 
transcription and expression, arousing interest 
among researchers in this field as possible causes 
of diseases[1]. The modification is a reversible 
reaction catalyzed by biological enzymes and its 
rate of occurrence depends on external factors 
including exposure to chemicals consumed in 
food or present in the environment.
Referred to as “epigenetic,” this modification 
is an essential mechanism for normal cells to 
sustain life. Therefore, an abnormality within 
this mechanism may result in diseases including 
cancer.
This report provides descriptions of “epigenetics” 
as a likely area of cancer research, including an 
introduction to epigenetics, its causal relationship 
with cancer and the current international trend in 
epigenetic-based cancer research.
2.2      What does epigenetic mean?
The word “epigenetic” is derived from epigenesis 
as opposed to ontogenetic preformation, a 
philosophy that prevailed in the biological field in 
the 17th-18th centuries. According to preformation, 
an individual l iving organism is established 
through a course of development from the 
potential properties it has inherently, whereas 
in epigenesis, the living organism undergoes 
internal and external effects sequentially in the 
process of ontogenesis, ultimately evolving into 
an individual.
At this time, “epigenetic” is a phenomenon 
that affects gene expression by a mechanism 
other than genomic mutation. Epigenetic-based 
research is expected to reveal the mechanism 
for suppression of gene expression, facilitating 
progress in the research on gene expression in 
various interdisciplinary fields (Figure 1).
2.2.1  Epigenetics in normal living organisms
Epigenetics play an important role in sustaining 
normal living organisms. The genome DNAs, 
which are extracted from the cells of the skin, 
heart or liver of a human body, are basically the 
same. Contrary to the description above, it has 
been reported that each gene in these cells has 
different expression patterns. This means that 
only genes associated with the formation of 
the skin, heart or liver are expressed. This type 
of suppression of gene expression is achieved 
through epigenetics, which develop in the 
process of cell differentiation after the genome 
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is determined. In other words, gene expressions 
of all the cells in the living organism (excluding 
germ cells) are controlled by epigenesis.
Epigenetic suppression of gene expression in 
normal somatic cells has been shown to inactivate 
the X-chromosome and genomic imprinting in 
the cells[2].
One of two X-chromosomes in a female cell, 
one inherited from the father and another from 
the mother, is inactivated. This means that 
usually, a female’s cells have mosaic patterns in 
which “inactivated cells with the X-chromosome 
inherited from the father” and “deactivated 
cells with the X-chromosome from the mother” 
are randomly mixed. Daughter cells inherit 
X-chromosomes deactivated at the early stage 
of embryonic growth through cell division. 
Inactivation of X-chromosomes in female cells 
compensates for the imbalance in the number 
of genes between the male, who has one 
X- chromosome and the female, who has two 
X-chromosomes.
A human has 23 chromosomes each inherited 
from both his/her mother and father, totaling 46 in 
one normal cell. The chromosome consists of a 
DNA-protein complex (chromatin). Therefore, there 
are two sets of genes in the cell, one is from the 
father and the other is from the mother. Gene imprinting 
is when the genes from the mother’s and father’s 
families express differently. The suppressed gene 
is referred to as an imprinted gene.
It has been reported that either of the two 
epigenet ic mechan isms ment ioned above 
occurs at an early stage of embryonic growth 
and differentiation. However, the details of 
their mechanism and significance to the living 
organism have not yet been revealed.
2.2.2   Epigenetic mechanism for suppression of 
gene expression
The epigenetic mechanisms for suppression 
of gene expression include DNA methylation, 
histone acetylation/methylation and chromatin 
remodeling (Table 1).
These epigenetic mechanisms are caused by 
modifications of enzymes in DNA or protein. 
Techniques such as the Sanger method could not 
detect the modification, because the modification 
is lost during the chemical treatment used 
for detection. Since no modification could be 
detected in a trace amount of sample, fewer 
studies have been repor ted on the causa l 
relationship between diseases and epigenetics. 
The bi - sulfite sequence method developed in 
1992 enabled detection of DNA methylated 
patterns in a trace amount of DNA sample. In 
addition, the DMH (differential methylation 
Figure 1:  Considerable research areas developed by
 epigenetic-based research
Mechanism Action
DNA methylation
It causes methylation of cytosine in the CpG sequence of genome DNA, 
inhibiting gene transcription or gene expression by disturbing access of 
transcription factors and some enzymes to the DNA.
Histone, acetylation and 
methylation
It causes acetylation or methylation in histone, changing the structure of a DNA 
complex, histone and others, and affecting gene transcription and expression.
Chromatin remodeling
It causes the chromatin structure to condense or relax, inhibiting or facilitating 
gene transcription or gene expression by controlling access of transcription 
factors and some enzymes in the chromatin (which is composed of DNA, 
histone and others).
Table 1:  Epigenetic mechanism for suppression of gene expression
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hybr idizat ion) method using micro ar rays 
developed in 2000 and the MethyLight method, 
a real time PCR method using fluorescent dyes 
reported in 2001, dramatically improve the DNA 
methylation detection accuracy and rate[3,4].
These innovative detection techniques have 
enabled research on the causal relationship 
between diseases such as cancer and DNA 
methylation. Therefore, researchers specializing 
in cancers have recently focused attention on 
DNA methylation. In the following paragraphs of 
this report, DNA methylation is highlighted and 
discussed.
2.2.3   Mechanism for suppression of gene
 expression by DNA methylation
In the process of DNA methylation, a methyl group 
binds to the 5th position of the cytosine base in 
the DNA molecule by DNA methyltransferase, 
producing 5-methylcytosine. Since methylation at 
site 5 does not affect base paring, 5-methylcytosine 
can pair with a guanine base. This means that 
DNA can be replicated normally. However, the 
structural difference of 5 -methylcytosine can 
affect gene expression.
General ly, gene expression requires gene 
regulatory protein and transcription factor to 
bind to the promoter region of the gene (the DNA 
sequence of the promoter region involved in gene 
transcription). During gene expression, the gene 
regulatory protein and the transcription factor 
bind to the promoter region, which prevents DNA 
methyltransferase structurally from approaching 
the DNA sequence in the promoter region. At this 
stage, DNA methylation cannot occur.
When most of the gene regulatory protein and 
the transcription factor are released from the 
promoter region, DNA methyltransferase can 
approach the DNA in the region. Accordingly, the 
DNA in the promoter region is readily methylated. 
The DNA, once methylated, is speci f ical ly 
bound by internal protein to prevent the DNA 
from being demethylated. This means that DNA 
methylation is maintained, with gene expression 
stably inhibited.
In addition, the methylation pattern occurring 
in a parent DNA chain is readily inherited by 
its daughter DNA chain through maintenance 
methylase. In other words, when the DNA 
is methylated in the genome in a cell, all its 
daughter cells will have the methylated DNA at 
the same site as those of their parent genome.
An especially important mechanism is that 
which occurs in the course of cell differentiation, 
for  example,  prevent i ng sk i n  cel l s  f rom 
transforming into heart, liver cells or any other 
cells except skin cells after cell differentiation.
2.2.4   DNA methylation in normal living
 organisms and that involved in diseases
DNA methylation inhibiting the expression of 
unnecessary genes in the living organism at the 
normal stage has been described. This suggests 
that DNA methylation is involved in diseases 
through the following: (i) DNA methylation 
occurring in any way at a different region from 
the normal region, inhibits the expression of 
essential genes for sustaining a living organism, 
or (i i) although the DNAs have been stably 
methylated in a normal region, when the same 
region is demethylated, this faci l itates the 
expression of unnecessary genes, which disturb 
the development of a normal living organism.
How this relates to cancer caused by DNA 
methylation will be discussed in Chapter 2.4.
2.3       Scientific publications in
          the field of epigenetic-based
          research
To analyze the trend in epigenetic-based research, 
the number of scientific articles published (from 
1993 to 2002) on epigenetic-based research was 
investigated using the keyword search function 
of PubMed, a database containing medical articles 
(Figure 2).
The result of the search for reports using the 
keyword “epigenetic” showed that the number 
of reports relatively increased in 1996 and 1998 
compared with those in the previous years, while 
it indicated a remarkable increase in 2000 and 
later. The search by the keywords “epigenetic and 
cancer” or “methylation and cancer” also showed 
almost the same results as those mentioned above.
In recent years, it has been reported that 
epigenetics might be involved in aging and 
diseases other than cancers, suggesting that the 
rapid increase in the number of articles reflects 
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the results of these studies. Specifically, this 
is the reason why the number of articles on 
epigenetic-based research drastically increased 
in 2000. At that time, as the Human Genome 
Project was approaching its end, epigenetic-based 
research began to attract greater attention as a 
post-genome target, and the useful techniques 
for detecting DNA methylation mentioned before 
were identified.
The increase in the number of  a r t icles 
mentioned above suggests that epigenetic 
research and epigenetic-based cancer research 
are rapidly growing new research fields.
2.4       Epigenetics can be linked to 
cancer
Progress in molecular biological research 
has contributed to the great dissemination of 
the realization that cancer may be caused by 
any anomaly in the genome or genes. In recent 
years, epigenetic-based research has attracted 
worldwide attention because it has been revealed 
that epigenetics may cause cancer[5].
2.4.1  What is cancer?
Cancer can be defined as a disease where: 
(i) cells proliferate uncontrollably , and (ii) the 
proliferated cells then invade a region generally 
occupied by other cel ls, and remain there 
(Molecular Biology of THE CELL, 3rd edition). 
When cancer cells having the characteristic 
defined in (i) remain in a fixed region, this is 
referred to as a benign tumor. Usually, a benign 
tumor can be completely cured by excising the 
affected area. However, it is difficult to treat 
cancer referred to as a malignant tumor because 
it invades neighboring tissues or metastasizes to 
other organs.
Recent progress in molecular biological 
research has widely disseminated the realization 
that the cause for inducing the behavior of cancer 
cells described in (i) and (ii), is the abnormality 
in the gene involved in genes such as the 
“oncogene” or the  “tumor suppressor gene.” 
It has been revealed that abnormal genes can 
largely be grouped into two types, qualitative and 
quantitative abnormality.
2.4.2   Cancer development by qualitative and
         quantitative abnormality 
Cancer development caused by qualitative 
abnormal genes has attracted the greatest 
attention because many abnormal genes (mutant 
genes) are found in cancer cells, and these are 
involved closely in cancer development as well as 
the malignant differentiation of cancer.
In the course of cancer development due to 
quantitative abnormal genes in cancer cells at 
the gene expression level, the normal cell cycle 
Figure 2: Scientific publications in the field of epigenetics (1993-2002)
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cannot be maintained. This is because redsuced 
or suppressed transcription activities of the tumor 
suppressor and DNA repair genes may lead to 
a decrease in proteins. An enhancement in the 
transcription activity level may cause cancer 
by increasing the amounts of oncogene and 
oncoprotein, disabling control of the cell cycle. 
This suggests that in addition to abnormalities in 
the genomic DNA itself, epigenetic factors can 
also be involved in cancer development.
2.4.3  Methylation of DNA in cancer cells
Methylated genome DNAs are frequently 
observed in a cancer cell. In recent years, the 
causal relationship between DNA methylation and 
cancers has been revealed.
Table 2 shows cancer types and the methylated 
genes. It has been reported that methylated genes 
have  been observed in various types of genes 
associated with every stage of the cell cycle 
including the tumor suppressor gene[6]. While 
some genes are commonly methylated in many 
types of cancers, other genes are methylated 
in specific types of cancers. This suggests the 
existence of different causal mechanisms for 
cancer depending on cancer type.
Col lect ing and col lat ing in formation on 
methylated genes to be integrated into a database 
for use as fundamental information may be a 
requirement for facilitating future research on 
cancer toward treatment.
2.4.4   The pattern of methylated DNA in cancer
         cells
Many patterns of methylated DNA patterns 
are observed in a cancer cel l [1] including a 
wide range of hypomethylation/demethylation[2] 
and site -specific (ex., a gene promoter region) 
hypermethylation[7,8].
Hypomethylation or demethylation has been 
reported to disable control of the expression 
of unnecessary genes in the cells which form 
each tissue or organ (for example, all the genes 
expressed in liver cells are not necessary for 
the gene expression of skin cells). This might 
lead to inducing instability in chromosomes and 
increasing the risk of abnormal development of 
cells. Hypomethylation is observed over a wide 
range of genes in many cases.
In site-specific hypermethylation, methylation 
has been concentrated in the specific region 
related to gene expression, that is, the gene 
promoter region. This leads to inhibition of 
expression of the tumor suppressor gene and 
the DNA repair gene, which play roles in the 
suppression of tumors or cancer development.
Table 3 shows differences in the patterns of 
methylated genes between normal and cancer 
cells.
Gene Gene function Cancer type
P14 (ARF) cell cycle
colon and rectum cancer, stomach 
cancer
P16 (INK4a) cell cycle
lymphoma, pancreatic cancer, colon 
and rectum cancer, stomach cancer
hMLH1 DNA repair
colon and rectum cancer, cervical 
cancer
BRCA1
DNA repair, cancer 
suppressor
ovarian cancer, breast cancer
MGMT DNA repair colon and rectum cancer, brain tumor
GSTP1 neutralization of toxicity liver cancer
DAPK apoptosis lymphoma
CDH1 cell adhesion esophageal cancer 
TIMP3 proteolysis inhibitor kidney cancer
APC tumor suppressor
stomach cancer, pancreatic cancer, 
liver cancer
Source: Author’s compilation based on a reference[6]
Table 2:  Methylated genes observed in cancer cells
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2.4.5   Substances possibly involved in DNA
         methylation
Recently, it has been shown that deficient or 
excessive intake of some substances contained in 
food might affect the methylation of normal cells.
Table 4 shows the substances, which have been 
reported to affect DNA methylation. Although 
details on the mechanism have not been revealed, 
it is suggested that when deficiency exists in 
any substance with a chemical structure that 
can provide a methyl group, hypomethylation 
(instable chromosomes) is likely to be induced in 
the DNA of cells[9-12]. 
It has been reported that ingesting particular 
foods (not containing choline and folic acid) 
containing an environmental pollutant such as 
arsenic may accelerate DNA hypomethylation 
in animal experiments. This means that further 
investigation is required to establish safety 
standards for arsenic.
2.4.6   Chemical substance deficiency-induced 
         cancers, and cancer prevention by
         supplementation of deficient substances
The causal relationship between deficiency of 
chemical substances that can provide a methyl 
group and cancer development has been studied 
since the mid -1980s. One report showed that 
cancer and tumors developed in the livers of 
experimental animals (rats) at a high rate of 
incidence by continuous feeding with food 
containing no choline for one to one and a half 
years. The DNA methylation patterns of their 
cells were different from .those of normal cells 
and exhibited hypomethylation. At that time, 
since sufficient techniques for detecting DNA 
methylation were not avai lable, no further 
detailed research was conducted.
At present, it is believed that the deficiency of 
chemical substances can be correlated with the 
increased risk of cancer development. Thus, the 
target of research has been changed to cancer 
Table 3:  Methylated genome DNAs observed in normal and cancer cells
Example of genome DNA sequence Normal cell Cancer cell
Repetitive DNA sequence with the 
same pattern such as CTG
methylation
demethylation 
(hypomethylation)
Viral sequences in human genome 
DNA
methylation
demethylation 
(hypomethylation)
Promoter region of tumor 
suppressor gene 
demethylation 
(hypomethylation) 
methylation
methylation
Table 4:  Substances possibly involved in methylation
Substance
Food containing the 
substance
Intake Methylation type Gene state
methionine animal protein deficiency hypomethylation unstable
Choline yolk deficiency hypomethylation unstable
folic acid green and yellow vegetables deficiency hypomethylation unstable
folic acid green and yellow vegetables deficiency methylation
inhibits tumor 
suppressor gene p53
Vitamin B12 egg, seafood deficiency hypomethylation unstable
Zinc shellfish deficiency hypomethylation unstable
selenium mushroom, sea weed deficiency hypomethylation unstable
Retinoic 
acid
eel, liver, yolk excess hypomethylation unstable
alcohol alcoholic beverages excess hypomethylation unstable
Arsenic
environmental pollution 
(contaminated drinking water)
excess? hypomethylation unstable
Source: Author’s compilation with reference to NCI HP and references[9-12]
24
S C I E N C E  &  T E C H N O L O G Y  T R E N D S
prevention by the supplementation of deficient 
chemical substances.
In 2000, a study was conducted on the effect of 
folic acid contained in food (fed for 1-2 months) 
on experimental animals (mice), whose genes 
were altered so that carcinoma of the colon 
and rectum could be induced[13]. In the group 
(folic acid group) to which food containing folic 
acid was given, the normal state of methylation 
was observed compared with the non folic acid 
group. In the group to which the food containing 
folic acid was continuously given prior to the 
development of intestinal tumors, a lower rate of 
polyp incidence was observed compared with 
the non folic acid group. However, giving food 
containing folic acid after tumor formation had 
no effect. This suggests that folic acid should be 
supplied at a proper timing to prevent cancer 
development.
2.5       Worldwide trend in
          epigenetic-based cancer
          research
Externa l  factors includ ing exposure to 
chemical substances in the environment, food 
and lifestyle may increase the risk of cancer 
development. To reduce the r isk of cancer 
development, external factors, which may induce 
cancer development, should be eliminated or 
controlled. This may be achieved by applying the 
results of epigenetic-based research.
As shown in Figure 3, epigenetic-based cancer 
research falls within the category of “studies on 
the elucidation of the oncogenic mechanism.” 
The resu lts of th is research may di rect ly 
contribute to the research on cancer prevention.
International epigenetic-based research has 
been progressing as part of the Post Genome 
Project for about five years in collaboration with 
EU members. In the U.S., a research project has 
also been launched.
Regrettably, in Japan, no international projects 
on epigenetic-based cancer research or research 
projects in collaboration with multiple domestic 
institutes have been launched yet.
2.5.1   Trend in epigenetic-based research
          in the U.S.
In the U.S., although no large-scale projects 
on epigenet ic - based resea rch have been 
launched, various workshops and conventions 
focusing on the ‘epigenetic’ theme have been 
held: “Diet, DNA methylation processes and 
health” supported by the NIH, FDA and the 
U.S. Nutr it ional Science Society in August 
2001, “Epigenet ics in Cancer Prevent ion: 
Early detection and risk assessment”at which 
resea rcher s  f rom the Cancer  Prevent ion 
Department, NCI, attended as the main members 
in December 2001, and “Cancer genetics & 
epigenetics” as part of the Gordon Conference 
in January 2003, in which studies on the causal 
relationship between epigenetic phenomena such 
as methylation and cancer development were 
presented and the possibility for further study 
Figure 3:  Cancer research map
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was discussed.  Additionally, in September 2002, 
the call for research on a new theme, “Diet, DNA 
methylation and other epigenetic events, and 
cancer prevention,” was announced. Researchers 
can apply for an NIH Research Grant (R01 or R21) 
for this. The NCI will allocate about 2.5 million 
dollars (3 million yen) to grants from the fiscal 
year 2004 budget.
2.5.2   Epigenetic-based research strategy in
         Europe (Human Epigenome Project)
Europe has launched an epigenetic - based 
research project ahead of the U.S. and Japan. 
A i m i ng a t  the  e luc idat ion of  epigenet ic  
information in the human genome, the Human 
Epigenome Consortium was formed in 1999. 
The Sanger Center (UK), Centre National de 
Genotypage (France), German Cancer Research 
Center, Berlin Institute of Technology, and Max 
Planck Institute of Molecular Genetics (Germany) 
have participated in the consortium as members.
In the first stage, the Human Epigenome Project 
focused on making a detailed methylated gene 
map. The map will be useful for further studies 
on epigenetics. 
Epigenomics, a biotechnology company based 
in Berlin (Germany), has also been participating 
in the project as a team member. Epigenomics 
(http//www.epigenomics.com) aims at the 
development of epoch -making technologies 
using the human genome including that of drugs 
tailored to individuals. Through joint research, 
the company has formed an internat ional 
business network and, furthermore, strengthened 
its business network in the U.S. by operating a 
branch in Seattle.
2.5.3   Building of a DNA Methylation Database
         in Germany
Germany has bui lt the world’s f i rst DNA 
methylation database[14,15]. Called MethDB, this is 
the first methylation database accessible to the 
Figure 4:  DNA Methylation DB (Example: Transfer of malignant melanoma to liver)
Source: HP of DNA Methylation DB
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public(http//www.methdb.net). As of September 
4 in 2002, 6,667 methylation data on 46 kinds 
of species, 160 kinds of tissues and 72 kinds of 
expression phenogenetics are contained in the 
database. The number of accesses to the database 
per month has increased on a monthly basis 
from 810 in June 2000 to 8,884 in July 2002. This 
database has incorporated various innovative 
ideas. One of them, stoichiological image data, 
in which gene expression phenogenetics is 
represented in a micro graphical format, is 
available to users (Figure 4).
This database contains a wide range of data on 
DNA methylation in cancer cells. It is expected to 
play an important role as a source of information 
for future epigenetic-based cancer research.
2.6      Conclusion
A lthough epigenet ic - based resea rch i s  
still at the development stage,  this area will 
undoubtedly progress rapidly and enlarge to 
eventual ly become an international trend. 
Therefore, Japan needs to refine its domestic 
research system for epigenetics, while paying 
strong attention to the current movement of 
international epigenetic research.
Listed below are the points to be considered 
when discussing the refinement of a system for 
future epigenetic-based cancer research under 
the leadership of the Japanese government.
(1) Enlargement of future epigenetic-based 
cancer research.
An interdisciplinary research group (across the 
fields of medical science, natural and physical 
science, food, nutrition, health, and immunology) 
should be formed for the epigenetic research 
project.
(2) Building of a domestic human epigenetic 
database.
Data on epigenetic research such as DNA 
methylation, conducted at each institute and 
university, should be integrated into the main 
database to allow researchers to use and share the 
data for disease prevention and diagnosis studies. 
The database can be controlled by a satellite 
system, meaning that the database is located at 
each institute and university, while the main 
database can be located in cyber-space.
(3) Giving epigenetic-based research the 
status of post-genome research.
In Japan, post-genome research has focused 
on the protein structure/function analysis and 
SNPs. Epigenetic-based research must also be 
positioned as a pillar of post genome research.
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